
New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1
The next-generation antibody-drug conjugate (ADC) ARX788 generated excitement when it received fast track designation from the FDA for patients with HER2-positive metastatic breast cancer and again when it yielded a significant improvement in progression- …